DGM
KROS icon

Darwin Global Management’s Keros Therapeutics KROS Stock Holding History

Darwin Global Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,687,135
Closed -$26.7M – 6
2024
Q4 		$26.7M Buy
1,687,135
+163,403
+11% +$8.49M 2.53% 5
2024
Q3 		$88.5M Sell
1,523,732
-2,170
-0.1% -$107K 7.2% 4
2024
Q2 		$68.8M Buy
1,525,902
+89,952
+6% +$4.83M 8% 5
2024
Q1 		$95.1M Buy
1,435,950
+375,523
+35% +$22.3M 12.66% 3
2023
Q4 		$42.2M Buy
+1,060,427
New +$33.3M 8.28% 5
2023
Q2 		– Sell
-31,386
Closed -$1.34M – 4
2023
Q1 		$1.34M Sell
31,386
-397,146
-93% -$20.1M 0.37% 4
2022
Q4 		$20.6M Buy
+428,532
New +$20M 12.81% 2
2022
Q1 		– Sell
-111,500
Closed -$6.52M – 7
2021
Q4 		$6.52M Buy
+111,500
New +$5.56M 1% 8
2021
Q3 		– Sell
-104,186
Closed -$4.42M – 16
2021
Q2 		$4.42M Buy
104,186
+17,299
+20% +$937K 0.71% 9
2021
Q1 		$5.35M Buy
+86,887
New +$5.5M 1.05% 8

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Darwin Global Management's KROS Position: Q1 2025 in Review

Darwin Global Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 1,687,135 shares — an estimated $26.7M sold.

Darwin Global Management first reported a position in KROS in Q1 2021 and held it in 10 quarters. The position peaked at $95.1M in Q1 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Darwin Global Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Darwin Global Management sold 1,687,135 Keros Therapeutics shares in Q1 2025, an estimated $26.7M.
  • Darwin Global Management first reported a position in Keros Therapeutics in Q1 2021 and held it in 10 quarters.
  • Darwin Global Management's Keros Therapeutics position peaked at $95.1M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Darwin Global Management's 13F filing for Q1 2025, filed 15 May 2025.